Hintapan, Mark A.
HRN: 27-82-61 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/21/2025
CEFTRIAXONE 1G (VIAL)
09/21/2025
09/28/2025
IV
2gm
Q24
Multiple Physical Injuries Sec To RCI
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes